Home / Market News / $BSX
fiscal.ai Corporate Catalyst Impact 85/100 ● negative

Boston Scientific Reports Q3 2026 Financial Results and Updates Full-Year Guidance

Oct 30, 2026, 2:02 AM UTC · Primary ticker $BSX

Boston Scientific reported Q3 2026 sales slightly up but lowered its full-year EPS guidance due to pricing pressures, product weakness, and a cybersecurity incident. The significant acquisition of Penumbra is now delayed to Q1 2027, adding to earnings drag from higher interest rates, indicating potential headwinds for the company's near-term financial performance.

Boston Scientific announced Q3 2026 results with a modest sales increase but significantly lowered its full-year 2026 adjusted EPS guidance. This downward revision is primarily attributed to persistent pricing pressures in China, weakness in key product lines (electrophysiology and Watchman), and the negative impact of a recent cybersecurity incident. Additionally, the $14.5 billion acquisition of Penumbra, a major growth driver, has been delayed to Q1 2027 due to regulatory hurdles, with higher interest rates exacerbating the earnings drag. This news signals significant near-term headwinds for Boston Scientific, impacting investor confidence and potentially leading to a negative stock reaction. The delay also creates uncertainty for Penumbra shareholders awaiting the acquisition's completion. Traders should consider the immediate negative implications for BSX due to the guidance cut and acquisition delay, and the prolonged uncertainty for PEN.

$BSX negative Lowered guidance, acquisition delay, operational headwinds
$PEN negative Acquisition delay, uncertainty
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.